Clinical manifestations of gadodiamide-related nephrogenic systemic fibrosis

Peter Marckmann*, L. Skov, K. Rossen, H. S. Thomsen

*Corresponding author af dette arbejde

    Publikation: Bidrag til tidsskriftArtikelForskningpeer review


    Aims: To further characterize the clinical signs and symptoms of nephrogenic systemic fibrosis, a new and serious disease affecting renal failure patients and caused by some Gd-containing contrast agents, including gadodiamide. Material: 22 cases of gadodiamide-related nephrogenic systemic fibrosis followed at the nephrology department of Copenhagen University Hospital Herlev. Method: Retrospective cohort study based on medical records, personal interviews and physical examinations. Results: Typical first signs of the disease were skin discoloration, induration and warmth, itching, constant pain and other neuropathic symptoms localized to the lower legs. First sign appeared in a median of 14 days (range 0-53 days) after gadodiamide exposure. Associated early symptoms included sleeplessness and transient, diffuse hair loss. The pre-dominant late symptom was symmetrical skin stiffness of extremities with or without restricted joint motion. Ten of 22 patients (45, 95% CI: 27 - 66%) were severely disabled due to contractures on the average of 29 months after being exposed to gadodiamide. Four patients died (18, 95% CI: 6-41). Patients perceived that intensive physiotherapy was effective in limiting disabling contractures. Conclusions: Signs and symptoms of nephrogenic systemic fibrosis vary over time and between patients. The disease leads to severe disability in a significant proportion of affected patients. Intensive physiotherapy may limit the development of contractures.

    Sider (fra-til)161-168
    Antal sider8
    TidsskriftClinical Nephrology
    Udgave nummer3
    StatusUdgivet - 1 mar. 2008


    Udforsk hvilke forskningsemner 'Clinical manifestations of gadodiamide-related nephrogenic systemic fibrosis' indeholder.